Aerosolization of viable Mycobacterium tuberculosis bacilli by tuberculosis clinic attendees independent of sputum-GeneXpert status

Demographic and symptomatic characteristics of the study cohort

We recruited consecutive presumptive pulmonary TB patients over the age of 13 who self-presented to two community clinics serving two high-density, peri-urban residential areas south-west of Cape Town, South Africa. The final study population consisted of 102 TB clinic attendees (Table 1) who underwent repeated bioaerosol sampling between 15 May 2020 and 27 May 2022.

Of the participants sampled, 52 were sputum-GeneXpert-positive (Group A); 20 were diagnosed as sputum-GeneXpert-negative TB (Group B), 19 based on chest radiography and one on clinical suspicion alone; and 30 were sputum-GeneXpert-negative and not diagnosed with TB during six months of follow-up visits (Group C). One participant initially categorized as Group C was reclassified to Group B following radiographic TB diagnosis after the second visit. Notified TB patients (Groups A and B) received standard short-course chemotherapy for six months comprising 2 months’ rifampicin, isoniazid, pyrazinamide, and ethambutol combination therapy, followed by 4 months’ rifampicin plus isoniazid. Aerosol sampling at the initial visit was performed immediately before initiation of TB treatment in those diagnosed with TB. Eight participants in Group C received short-course amoxicillin at initial presentation; no quinolones were prescribed. Through the study, 16 participants were lost to follow-up, four relocated, four refused further sampling, three died, and one presented with multidrug-resistant TB and was excluded. In total, there were 352 sampling visits with 72 participants completing all four visits: baseline, two weeks, two months, and six months post initial presentation.

There were some differences in the baseline characteristics of the three groups (Table 1): Group A recorded the lowest median age and prevalence of previous TB, Groups A and B had lower body mass indices (BMIs) than Group C, and individuals in Group B were older and had a higher prevalence of HIV infection. Notably, 45 participants (44.1%) had a history of previous TB.

At presentation (baseline sample), nearly all participants reported at least one symptom (Fig. 1A). The median number of symptoms was highest in Group A (Fig. 1B), as expected; however, all three groups reported weight loss, persistent cough, loss of appetite, and night sweats as the most prevalent symptoms (Table 2).

• Download figure
• Open in new tab

Fig. 1. Presentation of symptoms at baseline.

(A) Percentage of participants with one or more self-reported symptom. (B) Distribution of the number of symptoms per individual by diagnostic group; the median symptom number for Group A, B, and C was 3, 2, and 2, respectively.

Microbiological detection of Mtb in bioaerosol samples

Each participant produced bioaerosols from three distinct respiratory maneuvers – force vital capacity (FVC), tidal breathing, and voluntary cough. DMN-trehalose-positive Mtb bacilli with characteristic morphological appearance were detected for all three diagnostic groups. No significant differences were observed in the numbers of Mtb bacilli detected nor the prevalence of positive samples between the three respiratory maneuvers (Figs. S1A & B). Some individuals displayed a greater propensity for bacillary aerosolization in a single respiratory maneuver, however this was not consistent for all participants tested (Fig. S1C). Consequently, counts from respiratory maneuvers were pooled in subsequent analyses to compare participants in the three diagnostic categories, Groups A-C.

Surprisingly, despite the differences reported in symptom number and severity, we observed no significant differences in median Mtb counts across Groups A-C at baseline (Fig. 2A). Moreover, the prevalence of Mtb-containing bioaerosols was similar for all three groups (Fig. 2B), with Mtb detected in 92%, 90%, and 93% of bioaerosol samples in Groups A, B, and C, respectively. There were no clinical or demographic variables predictive of a positive Mtb bioaerosol (Table 3).

• Download figure
• Open in new tab

Fig. 2. The detection of Mtb bacilli in the bioaerosol of all three diagnostic groups at baseline.

(A) Counts of putative Mtb with medians 9, 4.5 and 8 (represented by the thick black bars) for Group A, B and C respectively. No difference was found between the groups with Wilcoxon Rank Sum testing after Bonferroni correction for multiple comparisons. (B) Percentage Mtb bioaerosol positive samples per diagnostic group. Owing to contamination of the slides, 4 samples were uninterpretable; these are not included in the denominator of the prevalence proportions

Secular trends in the detection of Mtb in bioaerosol samples

In compliance with SA National TB Control Program policy, sputum-GeneXpert-positive (Group A) and clinically diagnosed sputum-GeneXpert-negative (Group B) TB patients were immediately started on six months’ standard anti-TB therapy. Owing to the unexpectedly high baseline identification of aerosolized viable Mtb across all groups (A-C), we decided to monitor all participants for Mtb bioaerosol release and TB symptoms for six months at defined intervals, regardless of clinical TB diagnosis. Therefore, serial bioaerosol sampling was conducted at approximately two weeks (a two week timepoint was targeted but, in practice, the median was 19 days, IQR 10 days), two months (median 61 days, IQR 19 days), and six months (median 176 days, IQR 27 days) after initial enrolment (Fig. S2).

Mtb bioaerosol numbers and the percentage of Mtb-positive bioaerosol samples decreased equivalently in all three groups over the six months, irrespective of TB therapy (Fig. 3A). In Groups A and B – comprising notified TB cases – MTB was isolated in bioaerosol samples from 87% and 74% of participants at two weeks, 54% and 44% at two months, and 32% and 20% at six months, respectively, with similar numbers detected for Group C (70%, 48% and 22%, respectively, at the same timepoints). Notably, the decline in bioaerosol positivity corresponded with a reduction in symptoms for all three groups (Fig. 3B), and there were no notable differences in the numeric trends between any of the three groups (Fig. S3). Furthermore, no baseline predictors of Mtb bacillary clearance were identified at any of the timepoints (Fig. S4). The median time to clearance of Mtb bacilli from bioaerosol samples was 83 days (95% CI, 63 to 167 days) (Fig. 4A); stratification by treatment (Fig. 4B), previous history of TB (Fig. 4C), or HIV status (Fig. 4D), did not significantly alter the time to clearance (log-rank p-values 0.751, 0.404, and 0.798 respectively). The median time to TB symptom resolution was 168 days (95% CI, 166 to 176 days) (Fig. 5A). A previous history of TB (Fig. 5C) was associated with persistence of symptoms towards the end of the observation period for a minority of participants (log rank p-value, 0.026). There was no impact of treatment (Fig. 5B) nor HIV status (Fig. 5D) on rate of symptom resolution (log-rank p-values, 0.210 and 0.497, respectively).

• Download figure
• Open in new tab

Fig. 3:

The detection of Mtb bioaerosols decreased similarly in all three groups over six months.

(A) The percentage of bioaerosol samples that were positive for Mtb. The denominator is all visits yielding an interpretable sample. 13 samples were uninterpretable; these are not included in the denominator of the prevalence proportions. The error bars represent the standard error of the mean. Fisher’s exact tests performed on each visit found no significant differences. (B) A heat map indicating the prevalence of TB screening symptoms across visits. The numbers indicate the symptom proportion of patients in each group-visit combination with symptoms.

• Download figure
• Open in new tab

Fig. 4. Kaplan-Meier plots showing time to Mtb bacillary clearance from collected bioaerosol.

The first visit at which Mtb is not detected in the sample is considered the time to clearance. Individuals with detectable Mtb at the final visit are censored at the time of this visit. (A) All participants. (B) TB patients on treatment (Groups A & B) are separated from those individuals not diagnosed with TB and therefore not treated (Group C). (C) Comparison of time-to-clearance between those with a previous history of TB and those without. (D) Participants separated according to HIV status. The shaded areas represent 95% confidence intervals. Log rank test p-values are given in the top right corner for panels B, C and D.

• Download figure
• Open in new tab

Fig. 5.

Kaplan-Meier plots showing the proportion of individuals with any TB symptom (persistent cough, fever, weight loss, night sweats) against days since first sampling. The first visit without reported symptoms is considered the time to clearance. Participants with symptoms at the final visit are censored at time of this visit. (A) All participants. (B) Participants separated into TB patients on treatment (Group A, B) and those not diagnosed with TB and therefore not treated (Group C). (C) Comparison of participants with a previous history of TB and without. (D) Comparison of participants according to HIV status. The shaded areas represent 95% confidence intervals. Log rank test p-values are given in the top right corner for panels B, C and D.

To evaluate the possibility of a change in DMN-trehalose assay sensitivity over time, DMN-trehalose Mtb bacilli counts were assessed for correlation with calendar date for each group and visit combination. The proportion of the variation explained by time was a median of 3% (R-squared range: <0.01 to 0.15).

Microscopic characterization of Mtb bacilli from bioaerosol samples

Mycobacteria, including Mtb, demonstrate morphological and metabolic plasticity in response to environmental and antibiotic stresses (15–17). We reasoned that, if Mtb were exposed to antibiotics before aerosolization, a discernible change in bacterial morphology and/or metabolic state might be detectable between treatment groups. An important consideration before performing this analysis, however, was the previous observation that Mtb morphology, specifically cell length, can differ according to anatomical origin (18). To allow for data pooling, we first needed to confirm that the three maneuvers employed in this study produced Mtb from the same respiratory compartment. To this end, we compared the length distributions of Mtb detected from each respiratory maneuver at baseline (Fig. S5). No significant differences were evident, suggesting that all bacilli were aerosolized from the peripheral lung by a conserved mechanism (3,9).

As observed previously (19), we identified multiple DMN-trehalose staining profiles in Mtb bacilli captured from participant bioaerosols (Figs. S6A & S6B), with most baseline samples characterized by two or more distinct staining patterns (Fig. S6C). For further microscopic analyses, the six month sample was excluded as too few bacilli were detected to make reliable conclusions.

Polarity index, a metric summarizing the staining profile of synthetic trehalose probes along the medial axis, has previously been shown to differ significantly upon exposure to antibiotics (20). Comparing the average polarity index of bacilli from treated and untreated samples did not reveal significant differences at baseline or two weeks. However, the polarity index of Mtb from treated individuals was slightly higher at two months (Fig. 6A) and corresponded with a minor increase in cell length observed in the same samples (Fig. 6B). Despite these very slight changes in cell length and DMN-trehalose staining, no significant differences in clustering were observed between participants (Fig. S6), suggesting that the treatment effect on bacterial phenotype was minor.

• Download figure
• Open in new tab

Fig. 6. Examining the change in DMN-trehalose phenotype and Mtb cell length through time.

A comparison of (A) polarity index and (B) Mtb cell length between treatment groups at each visit. Polarity index is defined as the fluorescence intensity in arbitrary fluorescence units (AFU) of the brighter pole divided by the fluorescence intensity at the mid-cell. A Wilcoxon Rank Sum test was performed.

Genotypic and genomic confirmation of Mtb in bioaerosol samples

The apparent lack of a treatment effect on Mtb bioaerosol clearance was a surprising observation. To increase our confidence in the Mtb assignments based on DMN-trehalose fluorescence, a second bioaerosol sample was collected in parallel from a subset of participants. The presence of Mtb bacilli in these samples was assessed using either conventional Auramine O (n=44) and Ziehl-Neelsen (n=50) staining, or by means of a droplet digital (dd)PCR-based molecular assay targeting the Mtb-specific RD9 locus (n=40), as reported previously (7). Sequentially selected samples included both baseline and subsequent visits. All (40/40) of the samples investigated by ddPCR were RD9 positive, confirming the presence of Mtb genomes. In contrast, Auramine O staining was positive in 82% (36/44) of samples, while Ziehl-Neelsen acid-fast staining was negative for all samples assayed.

Attempts to culture Mtb organisms from bioaerosol samples proved mostly unsuccessful despite extending the incubation period to 50 days in liquid medium. Five samples which exhibited some growth were selected for whole-genome sequencing to ascertain the feasibility of detecting “transmitted” Mtb lineages using this approach (Table 4): two from sputum-GeneXpert-positive (Group A) participants, one baseline and one at six months, and three from sputum-GeneXpert-negative (Group C) participants, two at baseline and one at two months. Of these, only three samples provided data of sufficient quality to detect lineage-defining SNPs (21). On analysis, we determined that one sputum-GeneXpert-positive sample (Group A, baseline) and one sputum-GeneXpert-negative sample (Group C, baseline) belonged to lineage 4.9, with the third sample (Group C, baseline) belonging to lineage 4.3 (Table 4).

Study design and population

We recruited consecutive presumptive pulmonary TB patients over the age of 13 who self-presented to two community clinics serving two high-density, peri-urban residential areas south-west of Cape Town, South Africa. A study protocol was published in advance (24) with the primary aim to compare proportions of Mtb-containing aerosols between sputum-GeneXpert-positive (Group A) and sputum-GeneXpert-negative (Group B) TB patients. Assuming 20% bioaerosol positivity in Group B, and 100% positivity in Group A, a sample size of 250 was calculated to give 90% power to detect a difference between the groups (24). As an interim analysis showed no difference in the proportions of positive aerosols between Groups A and B, the study was discontinued after recruitment of 102 patients. Ascertaining the prevalence proportion in Group C was an exploratory aim and the isolation of a high bioaerosol-positive proportion in this group was unexpected. The detection of viable Mtb aerosols in the non-TB group, coupled with the concern that they might have unrecognized sputum-GeneXpert-negative TB disease, necessitated longitudinal monitoring and sampling equivalent to the treated TB patients. Sampling intervals of baseline, two weeks, two months, and six months were therefore applied to all three groups, A-C.

Sampling protocol and data collection

A direct sampling protocol was developed as previously described (24) and implemented with slight modifications (3). Briefly, the respiratory aerosol sampling chamber (RASC) is a HEPA-filtered enclosure designed for investigation of respiratory bioaerosol emissions from a single individual. The RASC accommodates a Tyvek-suited participant seated and sampled via a metallic elliptical cone which comfortably accommodates each participant’s head (10). A unidirectional airflow is created by a high-flow (300L per minute) bespoke cyclone collector connected at the cone apex which extracts bioaerosol into sterile phosphate-buffered saline (PBS). Air enters the collector via a tangential nozzle which generates a liquid cyclone with particle inertia leading to deposition of bioaerosol from the airstream onto the wet wall. The exit airflow from the cone reaches a velocity of 12.5m per second, enabling collection of expiratory aerosols. Seated participants were directed by a study nurse to complete a 15-minute sampling protocol comprising 5-minute sampling for each of 15 Forced Vital Capacity maneuvers (FVCs), tidal breathing, and 15 voluntary coughs . The bioaerosol samples were collected in three separate cones and assessed independently. Ozone sterilization and empty RASC sampling were performed between participants to control for contamination. No Mtb bacilli were identified in these empty RASC controls.

At each visit, questionnaires were completed to determine the presence of symptoms including persistent cough (>2 weeks), recent weight loss, night sweats, loss of appetite, fever, hemoptysis, myalgias, and anosmia.

Mtb detection methods

To confirm specificity of Mtb detection, both DMN-trehalose and conventional Mtb identification methods were employed. Additional assays could not be sequentially applied post DMN-trehalose staining, moreover the paucibacillary nature of the specimen precluded splitting of the sample. Therefore, for subsets of patient visits, additional bioaerosol sampling was performed in parallel to produce a second sample for investigation by Auramine O and/or Ziehl-Neelsen staining and/or DNA analysis using a droplet digital (dd)PCR-based technique.

Sampling processing

For each participant, bioaerosol material was captured in 5-10mL PBS during each of the three respiratory maneuvers. After centrifugation at 3000 × g for 10 min, the pellet was resuspended in 200μL Middlebrook 7H9 medium and stained with the DMN-trehalose probe (26). Following overnight incubation in media containing DMN-trehalose, washed samples were added to a nanowell device (26). The devices were sealed with adhesive film and centrifuged prior to visualization of the entire array by fluorescence microscopy. Detection and enumeration of fluorescent bacilli was based on DMN-trehalose incorporation and bacterial length and width assessments (19) by 2 separate microscopists for each sample, blinded to participants and controls.

Auramine O and Ziehl-Neelsen Staining

A selection of parallel samples which were not subjected to DMN-trehalose staining were processed for Auramine O and/or Ziehl-Neelsen assays. After overnight incubation in 200μL Middlebrook 7H9 medium, the aerosol pellet was smeared on a slide and microscopy performed using Auramine O fluorescent and/or Ziehl-Neelsen acid-fast staining in accordance with the MGIT procedure manual (50). Mtb H37Ra smears were prepared as positive controls for the staining techniques.

Mtb RD9 detection and quantification by droplet digital (dd)PCR

Extraction of Mtb genomic DNA was accomplished using a modified version of a previously published protocol (51) Mtb bioaerosol samples were incubated in 1:1 (v:v) GeneXpert buffer for 15 min, with vigorous shaking every 5 min. The buffer was neutralized by the addition of 1200 ul of dH20 and the sample was centrifuged at 16000 × g for 10 min. The supernatant was discarded, the pellet was resuspended in 20μL Tris-EDTA (10 mM Tris, 1 mM EDTA, pH 8·0) and the sample was frozen at -70 °C for 10 min. After thawing at room temperature, the DNA used for ddPCR. The primer/probe combinations and reaction conditions for Mtb RD9-specific ddPCR have been described previously (8). Serial dilutions of known concentrations of purified Mtb H37Rv genomic DNA were included as positive internal controls for ddPCR, and nuclease-free water was included as a negative control. Data generated from the ddPCR reactions were analyzed with the Umbrella pipeline (52) using only wells for which a minimum 10,000 droplets were detected.

Mtb whole-genome sequencing

Five samples with the highest number of RD9 copies following 50 days’ incubation of aerosol pellets (n=64) in 200uL Middlebrook 7H9-OADC medium at 37°C were selected for WGS. Prior to library preparation, DNA that had been extracted as described above was purified using AMPure XP magnetic beads as described in (53). Sequencing libraries were prepared using the Nextera XT kit and sequenced on an Illumina NovoSeq platform. WGS was analysed according to previously described methods (54). Briefly, reads were trimmed using Trimmomatic v0.39 (55) with a sliding window of 5:20 and retaining reads with a minimum length of 20 was used to trim reads. Reads were then mapped to the reconstructed ancestor of the MTBC (56) using bwa v0.717 (57) Duplicates were removed using Picard v2.9.1 (58), prior to using Samtools v1.5 (59) and varScan v2.2.4 (60) call variants, with filters to exclude sites with fewer than 10 reads support and minimum base quality scores of 20. The resulting VCF files were used to search for lineage-defining SNPs as described (21) Only lineage-defining SNPs supported by at least 20 reads with an average Phred quality score of at least 30 are reported.

Fluorescence microscopy

Imaging was performed on a Zeiss Axio Observer 7 equipped with a 100× plan-apochromatic phase 3 oil immersion objective with a numerical aperture of 1.4. Epifluorescent illumination was provided by a 475 nm LED and non-specific fluorescence was removed with a Zeiss 38 HE filter set. Images were acquired using the Zeiss Zen software, and quantitative data extracted using MicrobeJ (61).

Statistical analyses

The bioaerosol positivity proportions of groups A, B, and C were compared using a Fisher’s exact test and Mtb numbers with Wilcoxon rank sum tests. Unadjusted odd ratios were used to investigate the impact of baseline demographic and clinical variables on the likelihood of baseline Mtb bacillary count positivity. Further logistical regression analyses assessed whether bioaerosol clearance was associated with baseline variables. The three separate timepoints (two weeks, two months, and six months) were investigated for clearance. For each analysis, data were dichotomized into count trajectories that cleared by that visit, defined as “no detectable DMN-trehalose Mtb bacilli”, and those that did not clear. Additional analyses used the log-rank statistic for time to Mtb clearance and time to resolution of symptoms, defined as the first visit with “no detectable DMN-trehalose Mtb bacilli” and with no reported TB screening symptoms respectively. Clearance/resolution proportion for both outcomes were stratified by treatment (groups A and B vs group C), previous history of TB disease and HIV status. All statistical analyses were performed using R Core Team (2021) and the R software package, ‘survival’.

Ethics approval

This study was approved by the Human Research Ethics Committee (HREC/REF: 529/2019) of the University of Cape Town. Written informed consent, including for publication of medical details, was obtained from all participants, and assent was obtained from under 18-year-olds.

List of Supplementary Materials

Figure S1: (A) Counts of Mtb bacilli at the first visit for all groups, comparing each separate 5-minute respiratory maneuver; (B) Mtb bioaerosols were released during all three respiratory maneuvers; (C) Mtb bioaerosols were released during all three respiratory maneuvers.

Figure S2: The median time between visits was similar for all three groups: (A) The median days at each visit; (B) Table indicating the median days until the visit for each group; (C) Histogram of visits for all groups.

Figure S3: The secular trends in the number of Mtb detected in the bioaerosol of each diagnostic group.

Figure S4.1: Visit 2 (2-week) clearance of Mtb from the bioaerosol for each diagnostic and treatment group stratified by (A) diagnostic and (B) treatment groups. (C) The results of a logistic regression for odds of clearing the bioaerosol at this timepoint

Figure S4.2: Visit 3 (2-month) clearance of Mtb from the bioaerosol for each diagnostic and treatment group. (A) diagnostic and (B) treatment groups. (C) The results of a logistic regression for odds of clearing the bioaerosol at this timepoint

Figure S4.3: Visit 4 (6-month) clearance of Mtb from the bioaerosol for each diagnostic and treatment group. (A) diagnostic and (B) treatment groups. (C) The results of a logistic regression for odds of clearing the bioaerosol at this timepoint

Figure S5: The length distribution of Mtb aerosolized by each respiratory maneuver.

Figure S6: Variation in DMN-trehalose staining at baseline.

Figure S7: Dimensionality reduction of several morphological and staining characteristics comparing the average bacterial phenotypes from patients on and not on treatment.